title: Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.
abstract: Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs are currently approved for use in patients with advanced disease. Newer, more potent inhibitors have reached phase III clinical testing, meaning others are likely to follow. In 2009, pazopanib became the most recent TKI to receive FDA approval. This review sets out to discuss the key opportunities and challenges associated with TKI use in RCC, focusing particularly on pazopanib. We also review the current place of pazopanib in the management of patients with advanced disease, in what is a rapidly evolving therapeutic landscape.
authors.affiliation: Clinical Research Fellow.
authors.forename: Naveen S
authors.initials: NS
authors.lastname: Vasudev
authors.forename: James M G
authors.initials: JM
authors.lastname: Larkin
references.citation: Curr Oncol Rep. 2011 Apr;13(2):103-11
references.pmid: 21318618
references.citation: Nat Rev Urol. 2010 Jun;7(6):307-8
references.pmid: 20535144
references.citation: Clin Cancer Res. 2009 Dec 15;15(24):7582-7592
references.pmid: 19996202
references.citation: Eur J Cancer. 2012 Feb;48(3):311-23
references.pmid: 21689927
references.citation: Int Immunopharmacol. 2011 Jul;11(7):856-61
references.pmid: 21315783
references.citation: J Clin Oncol. 2012 May 10;30(14):1678-85
references.pmid: 22493422
references.citation: Oncogene. 2011 Mar 10;30(10):1183-93
references.pmid: 21057538
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4220-7
references.pmid: 19509175
references.citation: BJU Int. 2011 Oct;108(8 Pt 2):E250-7
references.pmid: 21599821
references.citation: Clin Med Insights Oncol. 2010 Oct 01;4:95-105
references.pmid: 20981133
references.citation: AJR Am J Roentgenol. 2010 Jun;194(6):1470-8
references.pmid: 20489085
references.citation: Br J Cancer. 2010 Apr 27;102(9):1371-7
references.pmid: 20389299
references.citation: Clin Pharmacol Ther. 2010 Dec;88(6):818-23
references.pmid: 20980999
references.citation: Cancer Biol Ther. 2010 Jan;9(1):15-9
references.pmid: 20009542
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: Onco Targets Ther. 2010 Oct 05;3:147-55
references.pmid: 21049083
references.citation: Clin Cancer Res. 2011 Aug 15;17(16):5443-50
references.pmid: 21828239
references.citation: Nat Rev Drug Discov. 2010 Jan;9(1):17-8
references.pmid: 20043026
references.citation: Invest New Drugs. 2012 Aug;30(4):1773-81
references.pmid: 21394443
references.citation: Eur J Cancer. 2013 Apr;49(6):1287-96
references.pmid: 23321547
references.citation: Anticancer Drugs. 2011 Jun;22(5):377-83
references.pmid: 21394020
references.citation: Invest New Drugs. 2012 Aug;30(4):1566-74
references.pmid: 21811833
references.citation: J Natl Cancer Inst. 2011 May 4;103(9):763-73
references.pmid: 21527770
references.citation: Br J Cancer. 2011 Mar 29;104(7):1144-50
references.pmid: 21386843
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: J Urol. 2008 Sep;180(3):860-5; discussion 865-6
references.pmid: 18635227
references.citation: J Clin Oncol. 2010 Jan 20;28(3):475-80
references.pmid: 20008644
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1280-9
references.pmid: 19171708
references.citation: Eur Urol. 2011 May;59(5):721-30
references.pmid: 21272993
references.citation: Cancer. 2010 Sep 15;116(18):4256-65
references.pmid: 20549832
references.citation: Nat Rev Urol. 2010 May;7(5):245-57
references.pmid: 20448658
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Semin Oncol. 2006 Oct;33(5):588-95
references.pmid: 17045088
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
references.pmid: 19967539
references.citation: JAMA. 2006 Jun 7;295(21):2516-24
references.pmid: 16757724
references.citation: Oncologist. 2011;16 Suppl 2:45-50
references.pmid: 21346039
references.citation: J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
references.pmid: 17202116
references.citation: Cancer. 2010 Dec 1;116(23):5400-6
references.pmid: 21105118
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1525-35
references.pmid: 20501804
references.citation: Cancer Res. 2010 Feb 1;70(3):1063-71
references.pmid: 20103651
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Hepatol. 2011 Jun;54(6):1237-43
references.pmid: 21145803
references.citation: AJR Am J Roentgenol. 2010 Jan;194(1):157-65
references.pmid: 20028918
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2557-64
references.pmid: 21576632
references.citation: Angiogenesis. 2010 Mar;13(1):1-14
references.pmid: 20012482
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Ann Oncol. 2012 Mar;23(3):714-721
references.pmid: 21653681